DUBLIN, Dec. 14, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global healthcare company. Under the terms of the agreement, upon the closing of the transaction, Alkermes will be entitled to a one-time cash payment of $92.5 million for the facility and related assets, subject to customary adjustments in accordance with the agreement.

都柏林，2023年12月14日/PRNewswire/-Alkermes plc（纳斯达克股票代码：ALKS）今天宣布，该公司已达成最终协议，将其位于爱尔兰阿思隆的开发和制造工厂出售给全球领先的医疗保健公司诺和诺德。根据协议条款，交易结束后，Alkermes将有权一次性获得9250万美元的现金支付，用于购买设施和相关资产，但须根据协议进行常规调整。

The transaction is expected to close in mid-2024, subject to certain closing conditions..

该交易预计在2024年年中结束，但须符合某些交割条件。。

'As we prepare to enter 2024 as a pure-play neuroscience company, we have continued our focus on aligning our infrastructure and cost structure with the projected needs of the business. Upon closing, we expect this transaction to drive operational efficiencies and enhance profitability over the long term,' said Richard Pops, Chief Executive Officer of Alkermes.

“随着我们作为一家纯粹的神经科学公司准备进入2024年，我们继续专注于使我们的基础设施和成本结构与业务的预期需求保持一致。Alkermes首席执行官理查德·波普斯（RichardPops）说，交易结束后，我们预计这笔交易将提高运营效率，并从长远来看提高盈利能力。

'I am particularly pleased to enter this agreement with Novo Nordisk as it offers our employees at this world-class, state-of-the-art GMP manufacturing facility in Athlone an exciting opportunity for growth.'   .

“我特别高兴能与诺和诺德签订这项协议，因为它为我们在阿思隆的这家世界一流、最先进的GMP制造工厂的员工提供了一个令人兴奋的增长机会。”。

'The acquisition of the Athlone facility represents an expansion of Novo Nordisk's global manufacturing setup and will provide Novo Nordisk with additional development and manufacturing capacity for current and future oral products,' said Thilde G. Hummel Bøgebjerg, Senior Vice President, Product Supply Emerging Technologies, Novo Nordisk.

诺和诺德产品供应新兴技术高级副总裁Thilde G.Hummel Bøgebjerg说：“收购Athlone工厂意味着诺和诺德全球制造体系的扩大，将为诺和诺德目前和未来的口腔产品提供额外的开发和制造能力。”。

'With this acquisition, we are excited to soon welcome approximately 400 highly skilled colleagues currently employed by Alkermes with valuable capabilities within oral drug development and manufacturing who will play a key role in serving even more patients with oral products.'.

“通过此次收购，我们很高兴很快欢迎Alkermes目前雇用的大约400名高技能同事，他们在口服药物开发和制造方面具有宝贵的能力，他们将在为更多的口服产品患者提供服务方面发挥关键作用。”。

Alkermes and Novo Nordisk also plan to enter into subcontracting arrangements to continue certain work currently performed at the facility for a period of time after closing of the transaction, which may continue through the end of 2025. This transaction is expected to be operating cost-neutral to Alkermes over the subcontracting period and thereafter, the transaction is expected to yield significant operating cost benefit and contribute to enhanced profitability.

Alkermes和诺和诺德还计划签订分包协议，在交易结束后的一段时间内继续目前在该设施进行的某些工作，这可能会持续到2025年底。预计该交易在分包期内的运营成本不会对阿尔科姆产生影响，此后，该交易有望产生显著的运营成本效益，并有助于提高盈利能力。

Alkermes will continue to retain all royalty revenues associated with products currently manufactured at the facility. .

Alkermes将继续保留与工厂目前生产的产品相关的所有特许权使用费收入。。

Alkermes will continue to manufacture its proprietary commercial products, VIVITROL®, ARISTADA®, ARISTADA INITIO® and LYBALVI®, at its Wilmington, Ohio manufacturing facility.

Alkermes将继续在其俄亥俄州威尔明顿的制造工厂生产其专有商业产品VIVITROL®、ARISTADA®、ARISTADA INITIO®和LYBALVI®。

About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders.

关于Alkermes plcAlkermes plc是一家全球生物制药公司，旨在开发神经科学领域的创新药物。该公司拥有一系列专有商业产品，用于治疗酒精依赖、阿片类药物依赖、精神分裂症和双相I型障碍，以及一系列临床和临床前候选药物，用于开发神经系统疾病。

Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com..

Alkermes总部位于爱尔兰都柏林，在马萨诸塞州沃尔瑟姆设有研发中心；位于爱尔兰阿思隆的研究和制造工厂；以及位于俄亥俄州威尔明顿的制造工厂。欲了解更多信息，请访问Alkermes的网站www.Alkermes.com。。

Note Regarding Forward-Looking StatementsCertain statements set forth in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the expected timeline, structure, impacts and anticipated financial and operational benefits of the transaction, including details relating to the closing of the transaction and expectations regarding the company's plans to enter into subcontracting arrangements with Novo Nordisk; and the company's expectations regarding its future financial plans, expectations and prospects, including anticipated royalty revenues and profitability.

关于前瞻性声明的注释本新闻稿中的某些声明构成1995年《私人证券诉讼改革法》修订版所指的“前瞻性声明”，包括但不限于以下声明：交易的预期时间表、结构、影响以及预期的财务和运营效益，包括与交易结束有关的详细信息以及公司与诺和诺德签订分包协议计划的期望；以及公司对其未来财务计划、期望和前景的期望，包括预期的特许权使用费收入和盈利能力。

The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties.

该公司警告称，前瞻性陈述本质上是不确定的。前瞻性声明既不是承诺也不是保证，它们必然会受到高度不确定性和风险的影响。由于各种风险和不确定性，实际业绩和结果可能与前瞻性声明中明示或暗示的业绩和结果存在重大差异。

These risks and uncertainties include, among others: that the transaction may involve unexpected costs, liabilities or delays; that a condition to the closing of the transaction may not be satisfied or waived in a timely manner or at all and may result in closing being delayed or not occurring; that a party may terminate the definitive agreement relating to the transaction prior to its consummation; the company may not realize the anticipated financial or operational benefits of the transaction; the unfavorable outcome of arbitration or litigation, including so-called 'Paragraph IV' litigation and other patent litigation which may lead to competition from generic drug manufacturers, or other disputes.

这些风险和不确定性包括：交易可能涉及意外成本、负债或延迟；可能无法及时或根本不满足或放弃交易交割条件，并可能导致交割延迟或不发生；一方可在交易完成前终止与交易有关的最终协议；公司可能无法实现交易的预期财务或运营利益；仲裁或诉讼的不利结果，包括所谓的“第四款”诉讼和其他可能导致仿制药制造商竞争的专利诉讼或其他纠纷。

VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license.

VIVITROL®是Alkermes，Inc.的注册商标。；ARISTADA®、ARISTADA INITIO®和LYBALVI®是Alkermes Pharma Ireland Limited的注册商标，由Alkermes，Inc.根据许可使用。

Alkermes Contacts:For Investors:  Sandy Coombs +1 781 609 6377For Media:      Katie Joyce +1 781 609 6806

Alkermes联系人：投资者：Sandy Coombs+1 781 609 6377媒体：Katie Joyce+1 781 609 6806

SOURCE Alkermes plc

SOURCE Alkermes plc公司